INTRODUCTION
Liver cirrhosis is a common hepatic disease in China, 3% of those with compensated cirrhosis progress into decompensated stage annually. 1 Prognosis of decompensated cirrhosis is usually poor with a 5-year survival rate of only 14-35% under conventional treatment. 2 Decompensated cirrhotic patients frequently develop acute-onchronic liver failure (ACLF), which is associated with high mortality rates. However, decompensated cirrhotic patients without ACLF were also at high risk of medium-term and long-term mortality, 12.6% at 3 months, and increased to 18.3% at 6 months, and 27.6% at 1 year. 3 Hence, it is crucial to find an objective, userfriendly, accurate, inexpensive and reproducible scoring system to prognosticate survival of decompensated cirrhotic patients without ACLF.
Currently, a few scoring systems, such as model for end-stage liver disease (MELD) score, 4 MELD-Sodium (MELD-Na) score, 5 Child-Turcotte-Pugh (CTP) score 6 and Chronic Liver Failure-consortium score for acute decompensated (CLIF-C ADs), 7 have been proposed for predicting prognosis and survival in liver cirrhosis. However, CTP score has some limitations such as a narrow score range of disease severity (7) (8) (9) (10) (11) (12) (13) (14) (15) and inclusion of subjective criteria such as hepatic encephalopathy and ascites. The MELD score fails to incorporate a central prognostic determinant, measures of systemic inflammation. In addition, owing to the involvement of the logarithm in calculations of MELD score, MELD-Na and CLIF-C ADs, clinicians have to use an online calculator or application making it impractical in busy clinical practice. Furthermore, MELD score incorrectly predicts mortality in about 15-20% of patients 8 and CLIF-C ADs presents 26% of incorrect predictions for 90-day mortality and has no data in predicting long-term (>1 year) mortality. 7 Activation of systemic inflammation was described in decompensated cirrhotic patients characterised by increased plasma and ascetic fluid concentration of cytokines and C-reactive protein (CRP), even in the absence of spontaneous bacterial peritonitis (SBP). 9, 10 Peripheral blood neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) are indicators of systematic inflammatory response and widely investigated as useful predictors of clinical outcomes especially in cardiac disease and malignancies. [11] [12] [13] [14] [15] More importantly, the predictive value of these inflammatory response markers for the prognosis of cirrhotic patients has also been demonstrated in recent studies. [16] [17] [18] Nomograms are graphical depictions of predictive statistical models for individual patients, 19 and they have been developed for various types of cancers. 13, 20 Moreover, nomograms provide a user-friendly interface, which does not require computer software for interpretation/ prediction. 21 The use of nomograms has compared favourably to the traditional staging systems for many critical diseases, and thus, it has been proposed as an alternative method or even as a new standard. 20, 22, 23 However, nomograms for predicting follow-up outcome for decompensated cirrhosis are scarce. This study aimed at using nomograms to investigate the prognostic role of inflammatory biomarkers in decompensated cirrhotic patients without ACLF and comparing the predictive capacity of an established nomogram model with MELD score, MELD-Na and CLIF-C ADs.
MATERIALS AND METHODS

Study population
Between 1 January 2010 and 31 December 2012, decompensated cirrhotic patients who referred to the First Affiliated Hospital of Wenzhou Medical University were enrolled as the development cohort of the study. We prospectively recruited hospitalised patients with the same clinical characteristics in the first affiliated hospital of Wenzhou medical University between 1 January 2013 and 1 January 2014 as the independent internal validation cohort. All patients were followed up every 3-6 months after hospital discharge. The typical items of the follow-up period include a review of general health, physician examination, ultrasound or computed tomography and laboratory tests. The outcome of each patient was recorded as survival or death. This study was approved by the institution ethics committee of the first affiliated hospital of Wenzhou Medical University, and written informed consents were obtained from participants or family members.
Inclusion and exclusion criteria
The inclusion criteria was as follows: (i) 
Data collection
Patients' demographic data, laboratory variables and clinical information, including age, gender, liver function test, blood routine test, coagulation parameters, creatinine, aetiology of liver disease, ascites, hepatic encephalopathy, the width of portal vein et al., were comprehensively collected at admission. Patients' blood samples were obtained from 5 to 8 am and were detected by Sysmex XE-2100 automated haematology analyzer (Sysmex Corporation, Kobe, Japan). The neutrophil, lymphocyte, monocyte and platelet counts were collected from blood routine test. The definitions of inflammatory response biomarkers, including NLR, PLR and LMR, were described as follows: NLR, neutrophil-tolymphocyte ratio; PLR, platelet count to lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio. The severity of ascites and the width of portal vein were measured by an experienced sonographer. Hepatic encephalopathy was diagnosed according to West Haven criteria. 30 The MELD score, MELD-Na and CLIF-C ADs were calculated using the model previously described. Hazard ratio (HR) and 95% confidence interval (CI) were calculated. A P value less than 0.05 was considered statistically significant. Nomograms for possible prognostic factors associated with 6-month, 1-year and 3-year survival were established with the rms package in R software. The performance of nomogram was evaluated by discrimination (Harrell's concordance index) and calibration (calibration plots and Hosmer-Lemeshow calibration test) and assessed by comparing nomogram-predicted vs. observed Kaplan-Meier estimates of survival probability, and bootstrap with 1000 resamples were applied to these activities. 31, 32 Comparisons between the nomogram, MELD score, MELD-Na and CLIF-C ADs were tested by the C-index with the rcorrp.cens function in the Hmisc package in R software. To further assess 6-month, 1-year and 3-year prognostic efficiency of the nomogram model, we compared time-dependent area under the receiver operating characteristic curve (td-AUC) between nomogram model, MELD score, MELD-Na and CLIF-C ADs with timeROC package in R software. 33 A larger C-index and td-AUC indicated more accurate prognostic stratification. We also plotted decision curves to assess the net benefits of nomogram, MELD score, MELD-Na and CLIF-C ADs assisted decisions at different threshold probabilities, compared with the net benefit of treat all/treat none strategies. 34 
RESULTS
Baseline characteristics
After exclusion of those who meet the exclusion criteria ( Figure S1 ), a total of 637 subjects with decompensated cirrhosis but not ACLF were enrolled into the development cohort. In the validation cohort, 157 patients were excluded from the study and the final 265 included patients finished the follow-up at 25 June 2016. Baseline characteristics of the two cohorts of the patients were listed in The optimal cut-off value for NLR and LMR The mean NLR and LMR were 4.3 AE 46 and 2.6 AE 1.4 respectively. X-tile software was used to determine the optimal cut-off values for NLR and LMR of overall survival, which were 5.7 and 1.1 respectively ( Figure S2 ). The v2 log-rank value of NLR and LMR were 61.82 and 51.88 respectively. Patients were divided into two groups for further analysis (NLR ≤5.7 and >5.7; LMR ≤1.1 and >1.1). Kaplan-Meier survival analysis revealed that NLR >5.7 and LMR ≤1.1 were significantly associated with decreased overall survival (P < 0.001). As showed in Table 2 , the patients in the group with NLR Values presented as N (%), mean AE s.d.
>5.7 had an older age, a lower albumin, a higher serum creatinine, a higher white blood count, a higher PLR, a lower LMR, a higher occurrence rate of ascites, a higher MELD score, a higher CLIF-C ADs and a significantly shorter survival time than which of patients in the group with NLR ≤5.7. Compared to patients with LMR >1.1, patents with LMR ≤1 had a higher alkaline phosphatase, a lower serum sodium, a higher white blood count, a higher NLR, a higher PLR, a higher occurrence rate of ascites and a significantly shorter survival time. More importantly, patients with NLR >5.7 or LMR ≤1 had a significantly higher mortality at 6-month, 1-year and 3-year than which of patients with NLR ≤5.7 or LMR >1.1.
Prognostic factors for 6-month, 1-year and 3-year mortality Baseline demographic, clinical and laboratory parameters, including inflammatory response biomarkers for the prediction of 6-month, 1-year and 3-year mortality, Neutrophil-to-lymphocyte ratio P Lymphocyte-to-monocyte ratio (Table S1 ). Subsequently, all of these significant factors above were entered into the multivariate Cox proportional hazards model to adjust the effects of covariates for 6-month, 1-year and 3-year mortality respectively. In that model, we demonstrated that age, NLR and PLR were independent prognostic factors for 6-month, 1-year and 3-year mortality of the decompensated cirrhotic patients without ACLF (Table 3) .
Prognostic nomogram for 6-month, 1-year and 3-year mortality To predict the 6-month, 1-year and 3-year mortality of patients with decompensated cirrhosis, a prognostic nomogram was depicted by multivariate Cox regression model analysis according to all the significantly independent indicators for 6-month, 1-year and 3-year mortality ( Figure 1 ). Each subtype within these variables was assigned a score on the point scale. By summing up the points assigned to each variable, we were easily able to draw a straight line down to determine the estimated probability of survival at each time point. The nomogram scoring system could be used for a more precise calculation of the survival predictions than drawing lines on the nomogram (Table S2) .
To determine the predictive accuracy of the nomogram, the Harrell's C-indexes for 6-month, 1-year and 3-year survival prediction were measured. The nomogram generated from the development cohort had c-indexes of 0.739 (95%CI: 0.690-0.787), 0.732 (95%CI: 0.691-0.773) and 0.719 (95%CI: 0.682-0.754), respectively. In addition, the calibration curves for probability of 6-month (Figure 2a ), 1-year (Figure 2b ) and 3-year (Figure 2c ) survival showed satisfactory accordance between nomogram prediction and actual observation.
Comparison of predictive accuracy for mortality between nomogram, MELD score, MELD-Na and CLIF-C ADs The predictive powers for prognosis of decompensated cirrhosis were compared for nomogram, MELD score, MELD-Na and CLIF-C ADs using calibration tests, tdROC and decision curve analysis. In the development cohort, the calibration curve showed that nomogrmbased predictions were in optimal agreement with actual observations (Figure 2 ). The C-indexes for 6-month, 1-year and 3-year survival prediction by MELD score, MELD-Na and CLIF-C ADs was statistically significantly lower than that by the nomogram (Table S3) . Figure S3 (a-c) showed the tdROC curves of nomogram, MELD score, MELD-Na and CLIF-C ADs for predicting the mortality of decompensated cirrhosis at 6-month, 1-year and 3-year, respectively, after the start of follow-up using tdROC analysis. The tdAUC showed the predictive performances of the nomogram were superior to MELD score, MELD-Na and CLIF-C ADs for determining the prognosis within these time intervals. The results of our analysis were also listed in Table S4 . We also plotted decision curves to assess the net benefits of nomogram, MELD score, MELD-Na and CLIF-C ADsassisted decision at different threshold probabilities, compared with the net benefit of treat all/treat none strategies. Consistent with the survival C-index and tdAUC, decision curve analysis showed that the nomogram was superior to MELD score, MELD-Na and CLIF-C ADs across the entire range of threshold probabilities ( Figure S4 a-c) .
Validation of the predictive accuracy of nomogram
In the validation cohort, the calibration curve showed optimal agreement between prediction and observation in the probability of 6-month, 1-year and 3-year survival in nomogram ( Figure S5 ). The C-index for the established nomogram to predict 6-month (0.812; 95% CI, 0.755-0.869), 1-year (0.806; 95% CI: 0.754-0.858) and 3-year survival (0.799; 95% CI: 0.756-0.843) was significantly higher than that of the MELD score, MELD-Na, and CLIF-C ADs (Table S3) . Consistent with the survival C-index, tdAUC ( Figure S3 d-f , Table S4 ) and decision curve analysis ( Figure S4 d-f ) also showed that nomogram was superior to MELD score, MELD-Na and CLIF-C ADs in the validation cohort.
Performance of the nomogram in stratifying risk of patients We determined the cut-off values by grouping the patients in the development cohort evenly into three subgroups after sorting by total points (high risk: 0-123.5, intermediate risk: 123.6-140.1 and low risk: ≥140.1); each group represented a distinct prognosis (Figure 3a) . After applying the cut-off values to group patients in the validation cohort, stratification into three risk subgroups also allowed significant distinction between Kaplan-Meier curves for survival outcomes (Figure 3b ).
DISCUSSION
Systemic inflammatory responses occur frequently in patients with advanced cirrhosis and portal hypertension, and are associated with severity of liver disease and prognosis. Recent studies have shown that hospitalised cirrhotic patients with inflammatory responses have more severe hepatic encephalopathy, and are more likely to develop hepatorenal syndrome. 10, [35] [36] [37] Inflammatory response is represented by the levels of neutrophils, lymphocytes, platelets, and acute-phase proteins, such as CRP and albumin. Thus, a series of combinations of these factors, such as NLR, LMR, PLR and AGR might be potential prognostic factors for decompensated cirrhotic patients. It is worthy to note that although CRP has been shown to be a superior marker of systemic inflammation in clinical setting, CRP is not a regular test at admission and influenced by other factors such as body weight, smoking, active alcohol consumption and insulin resistance. 38 Therefore, CRP was not selected as a baseline parameter in our study. In the present study, we demonstrated that NLR and LMR were significantly associated with poor prognosis of decompensated cirrhotic patients without ACLF. Furthermore, we established a predictive nomogram model based on these two biomarkers to evaluate the prognosis of patients with decompensated cirrhosis. Nomogram is a simple graphical representation of a statistical prediction model that generates a numerical probability if a clinical event and can allow doctors to standardise clinical decision-making using evidence-based and fully individualised tools. In the present study, we first generated and internally validated a new nomogram model consisting of age, NLR and LMR, which could be used to prognosticate survival of decompensated cirrhotic patients without ACLF on the medium (6 months), and long term (1 year and 3 years) . Second, we demonstrated that this nomogram model was significantly more accurate in predicting 6-month, 1-year and 3-year mortality than MELD score, MELD-Na and CLIF-C ADs. The nomogram had good discrimination and calibration both in the development cohort and internal validation cohort, as shown in the calibration plots.
Current prognostic nomogram included patients' age, NLR and LMR. Inclusion of these factors would help improve available risk stratification for decompensated cirrhosis with no ACLF. Consistent with previous studies by CANONIC study investigators reported, patient's age was selected as the predictor of mortality in decompesated cirrhotic patients with or without ACLF. 3 In addition, increasing age was also independently associated to HE development in cirrhotic patients, which leads to a worse prognosis than younger age. 39 The survival might be affected by age not only in relation to the clinical course of disease but also for unrelated concurrent morbidity. NLR is an emerging parameter that reflects systemic inflammation as well as the general nutrition status of patients. And it was recently reported to predict the outcomes in patients with stable cirrhosis, HBV-Related decompensated cirrhosis, nonalcoholic fatty liver disease and liver transplantation. 16, 17, 40, 41 The physiopathologic association between an elevated NLR and poor prognosis is complex and remains to be elucidated. Neutrophils and lymphocytes are two major cell components of immune system. The neutrophil count reflects ongoing inflammation, whereas the lymphocyte count represents the immune regulatory pathway. As a previous study indicated, the prevalence of circulating bacterial DNA in patients with stable cirrhosis was Linear predictor 6 m Survival probability 1 y Survival probability 3 y Survival probability Figure 1 | Prognostic nomogram, including age, NLR and LMR levels, for 6-month, 1-year and 3-year survival in decompensated cirrhotic patients without ACLF. The nomogram allows the user to obtain the probability of 6-month, 1-year and 3-year survival corresponding to a patient's combination of covariates. To use, locate the patient's NLR level and draw a line straight upward to the "Points" axis to determine the score associated with NLR. Repeat the process for age and LMR, and sum the scores together and locate this total score on the "Total Points" axies. Draw a line straight down to determine the likelihood of 6-month, 1-year and 3-year survival. ACLF, acute-on-chronic liver failure; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio.
approximately 40% and bacterial translocation was a common event in patients with advance and decompensated cirrhosis. 42 In another study included 17
patients with advanced cirrhosis and ascites, seven consecutively admitted patients showed the asymptomatic presence of bacterial DNA in both the blood and ascetic fluid. 43 Low-dose or subclinical endotoxemia was reported to be associated with a systemic inflammatory response and induces a rise in blood neutrophil count and fall in total lymphocyte count. 44 Therefore, we hypothesise that elevated NLR was a sign of subclinical endotoxemia and reflected the presence of bacterial translocation or even tendency of spontaneous bacterial peritonitis, which was a severe complication with decompensated cirrhosis and accounted for increased mortality. 45 Moreover, Taylor that circulating neutrophils exhibited impaired phagocytic function and bactericidal capacity and this dysfunction is a robust predictor of outcome of 90-day and 1-year survival in patients with cirrhosis. 46 This may give another insight into understanding the role of neutrophils in cirrhosis. LMR is calculated as the absolute count of lymphocytes divided by the absolute count of monocytes, and it has also been suggested to be associated with survival in patients with malignant diseases. 47, 48 More importantly, in a recent retrospective cohort study, Zhang et al. also found that low LMR was an independent predictive factor for mortality of patients with HBV-liver cirrhosis. 18 Increased monocytes count can lead to low LMR. Monocytes are central mediators of the immune response and play a crucial role in the pathogenesis of liver cirrhosis. Several studies have demonstrated that monocytes from patients with severe cirrhosis were associated with a decreased HLA-DR expression, reduced ability to secrete TNF-a and with lower iNOS expression and lower allostimulatory response. 49, 50 Down-regulation of HLA-DR expression on monocyte is usually associated with the immune dissonance and high bacterial complication. 51 Given the functions of monocyte were partially suppressed in severe cirrhosis, it might be a possible reason to explain the increased monocyte count for compensation. Therefore, decompensated cirrhotic patients with poor prognosis may have a high monocyte count but low monocyte function.
To the best of our knowledge, this was the first nomogram for predicting survival of decompensated cirrhotic patients without ACLF that was based on a prospective database with regular follow-up. The physicians could perform an individualised survival prediction through this easy-to-use scoring system. 52 For example, what is the predicting probability of 3-year survival for a decompensated cirrhotic patient with 60-year old, NLR = 4.5 and LMR = 2.0? First, we establish scores for these three variable values in the nomogram. We can see from figure 2 or table S2 that the corresponding score of 60-year old is 20, 43 for NLR = 4.5 and 46 for LMR = 2.0, respectively. Second, we obtain the total score by adding up all the scores obtained in the previous step (total score = 20 + 43 + 46 = 109). Third, we can obtain the probability of 6-month, 1-year and 3-year survival from Figure 2 or Table S2 . Total score=109 is equivalent to a probability of approximately 89% for 6-month survival, 84% for 1-year survival and 59% for 3-year survival (Figure S6) . Identifying subgroups of patients at different risk for poor survival might have an impact on the treatment or care option. This scoring system should help physicians to select patients who need additional therapy or intensive follow-up. In addition, this tool could provide information for patient stratification in the design of clinical studies, gaining better equivalence between study arms. In the past decade, several predictive scoring systems or stage system have been developed and validated for assessing prognosis in patients with advanced liver diseases. 4, 5, 7, [53] [54] [55] However, besides CLIF-C ADs, most predictive systems don't take into account systemic inflammatory response, which has been demonstrated to be significantly associated with progression of cirrhosis and related complications. 56 The important mechanisms of systemic inflammation in cirrhosis are related to translocation of bacterial products (i.e. lipopolysaccharide, bacterial DNA) or of viable organisms from the intestinal lumen to the circulation due to quantitative and qualitative changes in gut microbiota, impairment in intestinal mucosal barrier, increased epithelial permeability and impaired intestinal immunity. 3, 56, 57 However, other mechanisms remain further elucidated. Nevertheless, there were a few limitations to this study that warrant consideration. First, these data were collected from Chinese patients at a single centre; therefore, it was subject to selection bias. Second, inflammation biomarkers were not dynamically observed. Therefore, it remains unclear whether these markers were elevated stepwise with a progressively deteriorating patient condition. Third, our study did not assess the pro-inflammatory cytokines, such as TNF-a and IL6, which might be helpful in establishing a mechanism for the results.
In summary, the findings in our study indicate that NLR and LMR were independent prognostic biomarkers for 6-month, 1-year and 3-year survival in decompensated cirrhotic patients without ACLF. A novel prognostic nomogram with age, NLR and LMR can be recommended as a more accurate and practical model to evaluate prognosis for patients with decompensated cirrhosis. The current nomogram can also lead to enhancing patient stratification in clinical trials and population-based analyses and it is a useful method to inform patients in the clinic.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article: Figure S1 . Flow chart of patient selection for the study analysis. ACLF: acute-on-chronic liver failure; HIV: human immunodeficiency virus. Figure S2 . X-tile analyses of overall survival were performed using patients' data to determine the optimal cut-off values for NLR and LMR. The sample of decompensated cirrhotic patients was divided into development and validation cohorts. X-tile plots of development cohorts are shown in the left panels, with plots of matched validation cohorts shown in the smaller inset. The optimal cut-off values highlighted by the black circles in left panels are shown in histograms of the entire cohort (middle panels), and Kaplan-Meier plots are displayed in right panels. P values were determined using the cut-off values defined in development cohorts and applying them to validation cohorts. The optimal cut-off values for NLR and LMR were 5.7 (v2 = 61.82, P < 0.001) and 1.1 (v2 = 51.88, P < 0.001) respectively. NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyteto-monocyte ratio Figure S3 . Time-dependent ROC of the prognostic nomogram, MELD score, MELD-Na, and CLIF-C ADs for patients in development and validation cohorts.
Comparison of time-dependent ROC of the prognostic nomogram, MELD score, MELD-Na, and CLIF-C ADs for predicting 6-month survival (a), 1-year survival (b) and 3-year survival (c) in the development cohort and 6-month survival (d), 1-year survival (e) and 3-year survival (f) in the validation cohort. The time-dependent ROC curve was used to evaluate the prognostic performance for survival prediction. Performance comparison was assessed between the nomogram MELD score, MELD-Na, and CLIF-C ADs by calculating the area under the ROC curves. ROC, receiver operating characteristics; MELD, model for end-stage liver disease; MELD-Na, model for end-stage liver disease sodium; CLIF-C ADs, chronic liver failure-consortium score for acute decompensated. Figure S4 . Decision curve analyses for development cohort and validation corhort demonstrating the net benefit associated with the use of the nomogram, MELD score, MELD-Na, and CLIF-C ADs. Decision curves for 6-month survival (a), 1-year survival (b) and 3-year survival (c) in the development cohort and 6-month survival (d), 1-year survival (e) and 3-year survival (f) in the validation cohort. Solid thin line: net benefit of a strategy of treating all patients. Solid bold line: net benefit of treating no patients. Dotted line: net benefit of a strategy of treating patients according to the nomogram predictions, MELD score, MELD-Na and CLIF-C ADs. Compared with MELD score, MELDNa and CLIF-C ADs, the nomogram had a higher clinical net benefit across the entire range of threshold probabilities. MELD, model for end-stage liver disease; MELD-Na, model for end-stage liver disease sodium; CLIF-C ADs, chronic liver failure-consortium score for acute decompensated. Figure S5 . The calibration curves of nomogram, MELD score MELD-Na, and CLIF-C ADs for predicting 6-month (a), 1-year (b) and 3-year survival (c) in the validation cohort of patients with decompensated cirrhosis. The average predicted probability (predicted overall survival; x-axis) was plotted against the Kaplan-Meier estimate (observed overall survival; y-axis). 95% CIs of the KaplanMeier estimates are indicated with vertical lines. Dashed line indicates the reference line, indicating where an ideal would lie. MELD, model for end-stage liver disease; MELD-Na, model for end-stage liver disease sodium; CLIF-C ADs, chronic liver failure-consortium score for acute decompensated; CI, confidence interval. Figure S6 . Example for nomogram predicting the probability of 6-month, 1-year and 3-year survival in decompensated cirrhotic patients. A decompesated cirrhotic patient was 60 year old (score % 20) with NLR 4.5 (score % 43) and LMR (score % 46); the total risk score for him was 20 + 43 + 46 = 109; total score = 109 is equivalent to a probability of approximately 89% for 6-month survival, 84% for 1-year survival and 59% for 3-year survival. ACLF, acute-on-chronic liver failure; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyteto-monocyte ratio. Table S1 . Unvariate analysis of prognostic factors in the development cohort of patients with decompensated cirrhosis. Table S2 . Overall survival nomogram scoring system. Table S3 . The comparison of C-index of Nomogram, MELD score, MELD-Na and CLIF-C ADs for prognosis in the development cohort and validation cohort. Table S4 . The comparison of time-dependent AUC of Nomogram, MELD score, MELD-Na and CLIF-C ADs for prognosis in the development cohort and validation cohort.
Data S1. The screening protocol for infections.
